Global CAR-T cell therapy market valuation to surpass USD 8.92 billion by 2026

The latest ‘global CAR-T cell therapy market’ report is rich source of information for businesses, investors, VPs, and new entrants to gain a better understanding the current business scenario and the steps to be taken for strong returns during 2020-2026.

Selbyville, Delaware , Oct. 14, 2020 (GLOBE NEWSWIRE) -- Worldwide CAR-T cell therapy market size is projected to showcase a y-o-y growth rate of 34.5% during 2020-2026, subsequently accounting for USD 8.92 billion by the end of the forecast period. As per the report findings, rising burden of cancer worldwide is primary growth driver of the industry. Moreover, spike in cases of failure response to alternative therapies is reinforcing the demand for Chimeric Antigen Receptor (CAR) T cell therapy.

Key growth drivers and opportunities along with threats and challenges have been factored to decipher the future trajectory of this business sphere. Moreover, it offers a detailed segmentation of the industry, inclusive of target antigen, indication type, and geographical ambits. In addition, the study boasts of a comprehensive analysis of the evolving competitive dynamics and key players in the market. 

For those uninitiated, cancer is one of the leading causes of deaths globally, urging companies to introduce various conventional and cytotoxic immunotherapies into the market. Moreover, the complex nature of tumours has prompted organizations to find new treatments that could potentially eliminate cancer at both cellular and genetic level, giving impetus to CAR-T cell therapy industry.

CAR-T cell therapy is a novel therapeutic treatment wherein cancer patient’s white blood cells are extracted, reengineered, and injected back into the body. The restructured cells then multiply and combat the infected cells. As of now, CAR-T cell therapy has shown strong promise in patients suffering from blood cancer or hematologic cancer particularly for non-hodgkin lymphomas.

*Request Sample copy of this Report @ *https://www.marketstudyreport.com/request-a-sample/2963751/

Despite the high success rate of this therapy, the number of patients relapsing months after the treatment is a major concern for global CAR-T cell therapy market growth. Apart from this, complexities associated with manufacturing process of CAR-T cells, logistics challenges faced by healthcare organizations, along with expensive treatment, and poorly defined reimbursement policies are obstructing the industry expansion.

*Target antigen overview: *

Global CAR-T cell therapy is categorized into CD19/CD22, BCMA, and others, among which, the foremost segment is anticipated to capture the largest market share by the year 2026. The strong growth is creditable to high approval rate of the antigens and their commercialization since 2017.

Meanwhile, BCMA (B-cell maturation antigen) segment is anticipated record a robust growth rate growth over the projected timeline, and the others segment is likely to account for a significant portion of the market revenue in the long run.

*Indication review: *

Global CAR-T cell therapy industry is split among Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma (DLBCL), Multiple Myeloma (MM), and others. As per trusted projections, Diffuse Large B-Cell Lymphoma (DLBCL) currently captures the largest market share and is estimated to record strong CAGR through 2026. Whereas, Multiple Myeloma (MM) segment is set to register a hefty yearly growth rate over the analysis timeframe.

*Regional outlook: *

United States is a prime contributor to global CAR-T cell therapy market remuneration, followed by Europe. Continuous R&D activities, ongoing regulatory approvals for new therapies, and establishment of cancer awareness programmes by major players are supporting the industry expansion in the United States.

On the other hand, the growth of Europe CAR-T cell therapy market is largely attributable to European Medicines Agency’s approval for the use of Kymriah and Yescarta drugs in the region. Meanwhile, APAC market is still at a nascent stage with Japan’s Ministry of Health, Labor and Welfare (MHLW) being the first regulatory authority to pass a greenlight for the administration of Kymriah.

*To access a sample copy or view this report in detail along with the table of contents, please click the link below: *

https://www.marketstudyreport.com/reports/car-t-cell-therapy-market-share-size-trends-industry-analysis-report-by-target-antigen-cd19-cd22-bcma-others-by-indication-diffuse-large-b-cell-lymphoma-dlbcl-acute-lymphoblastic-leukemia-all-chronic-lymphocytic-leukemia-cll-multiple-myeloma-mm-follicular-lymphoma-fl-others-by-regions-segment-forecast-2020-2026

*Competitive landscape:*

The competitive environment of global CAR-T cell therapy industry is dynamic with major players vying to improve their market share across US and Europe. For instance, Gilead and Novartis established 28 and 33 authorized centers respectively in the United States.

In addition to expanding their geographical presence and acquiring the requisite government approvals, companies are also undertaking strategies such acquisitions, mergers, and partnerships. In fact, in November 2018, Celgene acquired Juno Therapeutics for about USD 9 billion, and in the same month of the following year, Bristol-Myers Squibb acquired Celgene.

*Global CAR-T Cell Therapy Market Target Antigen Sub-segments (Revenue, USD Million, 2017-2026)*

· BCMA
· CD19/CD22
· Others
*Global CAR-T Cell Therapy Market Indication Sub-segments (Revenue, USD Million, 2017-2026)*

· Diffuse Large B-Cell Lymphoma (DLBCL)
· Chronic Lymphocytic Leukemia (CLL)
· Acute Lymphoblastic Leukemia (ALL)
· Follicular Lymphoma (FL)
· Multiple Myeloma (MM)
· Others
*Global CAR-T Cell Therapy Market Regional Bifurcation (Revenue, USD Million, 2017-2026)*

· Europe
· United States
· Japan
· Rest of the World
*Global CAR-T Cell Therapy Market Competitive Backdrop*

· Sangamo Therapeutics Inc.
· Pfizer Inc.
· Novartis International AG
· Noile-Immune Biotech Inc.
· Nanjing Legend Biotechnology Co. Ltd.
· Merck KGaA
· Johnson & Johnson
· Intellia Therapeutics
· Gilead Sciences Inc.
· Celyad Oncology
· Cellectis
· Celgene Corp. (acquired by Bristol-Myers Squibb)
· Caribou Biosciences Inc.
· Bluebird Bio Inc.
· Bellicum Pharmaceuticals Inc.
· Amgen Inc.
*Table of Content:*

*1. Overview and Scope*

1.1.         Research goal & scope

1.2.         Research assumptions

1.3.         Research Methodology

1.3.1.     Primary data sources

1.3.2.     Secondary data sources

1.4.         Key take-aways

1.5.         Stakeholders

*2. Executive Summary*

2.1.         Market Definition

2.2.         Market Segmentation

*3. CAR-T Cell Therapy Market - Premium Insights*

3.1.         CAR-T Cell Therapy- Industry snapshot

3.2.         CAR-T Cell Therapy- Ecosystem analysis

3.3.         CAR-T Cell Therapy Market dynamics

3.4.         Industry analysis - Porter's five force analysis

3.5.         CAR-T Cell Therapy Market PEST analysis, 2019

3.6.         CAR-T Cell Therapy Industry trends

3.7.         Competitive Ranking Analysis

3.8.         Timeline of CAR-T Cell Therapy Development

3.9.         CAR-T Cell Manufacturing Process

3.10.      Side-effects of CAR-T Cell

*4. CAR-T Cell Therapy Market Size and Forecast 2017 - 2026 by Target Antigen*

4.1.         Key findings

4.2.         CD19/CD22

4.3.         BCMA (B-Cell Maturation Antigen)

*5.  CAR-T Cell Therapy Market Size and Forecast by Indication*

5.1.         Key findings

5.2.         Diffuse Large B-Cell Lymphoma (DLBCL)

5.3.         Acute Lymphoblastic Leukemia (ALL)

5.4.         Chronic Lymphocytic Leukemia (CLL)

5.5.         Multiple Myeloma (MM)

5.6.         Follicular Lymphoma (FL)

*6. CAR-T Cell Therapy Market Size and Forecast by Regions*

*Related Report: *

*Stem Cell Therapy Market Size, Technology Potential, Competitive Market Share & Forecast, 2019 – 2025*

Stem Cell Therapy Market will exceed USD 15 billion by 2025, as per a new research report. Increasing research on developing novel therapies and personalized medicines will foster stem cell therapy market growth. For instance, scientists are extensively researching on methods to regenerate healthy heart cells from placenta that can be used in patients after myocardial infarction. This discovery will help to cure patients suffering from cardiovascular diseases and reduce mortality rates. Researchers are further examining different aspects of stem cell therapy for its applications in neurological disorders. Thus, increasing R&D activities to promote developments in stem cell therapy will positively impact the industry growth.

*About US:*

Market Study Report, LLC. is a hub for market intelligence products and services.

We streamline the purchase of your market research reports and services through a single integrated platform by bringing all the major publishers and their services at one place.

Our customers partner with Market Study Report, LLC. to ease their search and evaluation of market intelligence products and services and in turn focus on their company's core activities.

If you are looking for research reports on global or regional markets, competitive information, emerging markets and trends or just looking to stay on top of the curve then Market Study Report, LLC. is the platform that can help you in achieving any of these objectives.

CONTACT: Contact Us:
Corporate Sales,
Market Study Report LLC
Phone: 1-302-273-0910
Toll Free: 1-866-764-2150
Email: sales@marketstudyreport.com